Research | Open | Published:
Enterovirus 71 viral capsid protein linear epitopes: Identification and characterization
Virology Journalvolume 9, Article number: 26 (2012)
To characterize the human humoral immune response against enterovirus 71 (EV71) infection and map human epitopes on the viral capsid proteins.
A series of 256 peptides spanning the capsid proteins (VP1, VP2, VP3) of BJ08 strain (genomic C4) were synthesized. An indirect enzyme-linked immunosorbent assay (ELISA) was carried out to detect anti-EV71 IgM and IgG in sera of infected children in acute or recovery phase. The partially overlapped peptides contained 12 amino acids and were coated in the plate as antigen (0.1 μg/μl). Sera from rabbits immunized with inactivated BJ08 virus were also used to screen the peptide panel.
A total of 10 human anti-EV71 IgM epitopes (vp1-14 in VP1; vp2-6, 21, 40 and 50 in VP2 and vp3-10, 12, 15, 24 and 75 in VP3) were identified in acute phase sera. In contrast, only one anti-EV71 IgG epitope in VP1 (vp1-15) was identified in sera of recovery stage. Four rabbit anti-EV71 IgG epitopes (vp1-14, 31, 54 and 71) were identified and mapped to VP1.
These data suggested that human IgM epitopes were mainly mapped to VP2 and VP3 with multi-epitope responses occurred at acute infection, while the only IgG epitope located on protein VP1 was activated in recovery phase sera. The dynamic changes of humoral immune response at different stages of infection may have public health significance in evaluation of EV71 vaccine immunogenicity and the clinical application of diagnostic reagents.
Human enterovirus 71 (EV71) is one of the major causative pathogens for human hand foot and mouth disease (HFMD). EV71 was first isolated in California in 1969. HFMD is common infectious disease frequently occurring in infants and children. Although it usually has no life threatening, the most severe neurological disease caused by EV71 may cause death. Therefore, EV71 is widely considered as one of the most important virulent neurotropic enteroviruses after the eradication of poliomyelitis .
During the last decade, outbreaks of HFMD have occurred worldwide and the incidence rate was significantly increased throughout the Asia-Pacific region [2–8]. The continuing increased HFMD epidemics in China over the last 3 years indicated HFMD has been an important public health concern [6–8]. Due to the absence of effective antiviral therapy for severe EV71 infections, the development of efficacious vaccine is a top priority to effectively prevent this disease.
EV71 is a picornavirus, belonging to the type A non-polio enteroviruses family . It has a positive sense linear single stranded RNA genome of approximately 7,400 nucleotides, with a single open reading frame that encodes 4 capsid proteins (VP1-4). VP4 is located inside the virus capsid and connected tightly with the viral genome. Other three proteins (VP1-3) are exposed outside of the capsid and consequently immunologically reactive epitopes may reside in these proteins .
Previous studies using animal infectious models to develop vaccine found that majority of neutralizing antibody were elicited by the epitopes on VP1 protein [11–14]. Therefore, most relevant researches have focused on VP1 protein but neglecting the fact that VP2 and VP3 are also important components of EV71 virion. They play a role in eliciting immune responses during infection. Until now, no human epitope has been identified on VP2 and VP3 proteins. Usually, an acute viral infection should lead to certain epitope inducing an IgM response, which is a significant marker for early diagnosis of disease, as well as for the prompt treatment of the severe cases. However, almost all of the known epitopes on VP1 only elicit an IgG response.
To extend the range of defined EV71 epitopes, we employed a panel of synthetic peptides covering all three external capsid proteins (VP1-3) as antigen to screen IgM and IgG antibodies specifically for EV71 epitopes. The EV71 sera were obtained from infected children at different stages of infectious disease (the acute or recovery stage). Convalescent sera from rabbits were immunized with inactivated BJ08 strain EV71 virus.
Materials and methods
Virus antigen and antigen peptides synthesis
Virus particles of EV71 BJ08 strain isolated from throat swab samples of EV71 infected children in Beijing in 2008  were inactivated as antigen for rabbit immunizations. The inactivated EV71 virus with 95% purity was kindly provided by the National Vaccine & Serum Institute (Beijing, China) at a concentration of 27.4 μg/ml.
A series of 256 overlapping peptides (each 12 amino acids with a 9 amino acid overlapping), were synthesized based on the deduced amino acid sequence of the VP1, VP2 and VP3 proteins of EV71 BJ08 strain. The purity of the synthesized peptides exceeded 70%. A peptide from the surface antigen of Hepatitis B virus (S28-39 - IPQSLDSWWTSL) was synthesized as a control. All peptides were resuspended in dimethyl sulfoxide at a concentration of 10 mg/ml stock solution at -20°C. A fresh working solution with a final peptide concentration of 0.1 μg/ml was prepared for coating antigen.
SPF grade New Zealand White female rabbits weighing 1.75-2.25 kg were used for experiments. All animals were purchased from Resource Center for Experimental Animals of the National Institute for Food and Drug Control, China.
Human sera specimens
Eight anti EV71 sera were collected from infected children in acute stage of HFMD (defined as within 3 days after the appearance of the first symptoms). All sera samples were confirmed as EV71 virus positive by PCR detection of viral RNA , and were verified as no cross-reactivity for CA16 by microneutralization assay. Eleven recovery sera samples (defined as 2 month after illness onset) were also collected from recovered children. All sera samples were collected by CDC in Jiangsu Provence, China.
Sera from 4 healthy individuals with negative anti EV71 IgM and/or IgG (screened by microneutralization assay  and an in vitro indirect ELISA assay) were used as controls in this study.
Viral RNA extraction and PCR amplification 
Viral RNA was extracted from clinical specimens using a QIAamp Mini viral RNA Extraction Kit (Qiagen) according to the manufacture's protocol. The primers used for RT-PCR are cited from reference 16. RT-PCR amplification was performed using AccessQuickTM RT-PCR kit (Promega). Cycle variables were reverse transcription at 45°C for 45 min, denaturation at 94°C for 5 min followed by 35 cycles at 95°C for 40 sec, 53°C for 40 sec, 72°C for 40 sec; and then a final elongation step at 72°C for 5 min. The second round amplification was performed in 25 μl volumes, which contains 2.5 μl 10 × PCR reaction buffer, 1 μl 10 mM dNTP, 0.5 μl 10 mM each primer, 0.5 μl Taq (TaKaRa), 1 μl of the first-round PCR product, and 19 μl Nuclease-Free Water, under the same conditions as the first-round PCR, except reverse transcription step. The PCR products were examined by electrophoresis with a 3.0% agarose gel.
Preparation of rabbit anti EV71 serum
Rabbit blood collected before immunization was used to generate negative control sera. Equal volumes of heat-inactivated EV71 BJ08 strain and complete Freund's adjuvant were thoroughly mixed to produce an emulsion. Then the mixture of 3 ml was injected intramuscularly into the rear foot pads and inner thigh muscles of a rabbits. Boosting immunizations were administered at day 7, 14, 28 and 42 post primary immunizations using the same method with a exception of replacing Freunds's complete adjuvant with incomplete adjuvant. Fourteen days after the last immunization, blood was collected by cardiac puncture, and the sera were obtained and stored at -20°C.
Indirect ELISA assay for detecting anti EV71 IgM and IgG
Purified EV71 viral particles were diluted to a final working concentration (0.01 μg/μl); meanwhile, the synthetic peptides were diluted to a final concentration of 0.1 μg/μl in carbonate buffer (0.1 M pH9.6). These antigen solutions were then coated separately into wells of a 96-well ELISA plate using 50 μl per well. The plate was kept at 4°C over night, washed once with phosphate buffered saline containing 0.05% Tween-20 (PBST), blocked for 2 hours with 100 μl per well of casein buffer. Then 50 μl of appropriately diluted serum was added to each well and incubated at 37°C for 30 min. The plate was then washed 5 times with PBST, followed by adding 50 μl horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG or goat anti-human IgG or goat anti-human IgM (all diluted 1:40,000) and incubated for a further 30 min at 37°C, and the plate was wash for 5 times with PBST. For visualization, 100 μl of TMB substrate solution was added into each well and incubated at 37°C for 10 mins in a dark situation. The optical densities (OD) were measured at both 450 nm and 630 nm within 10 min after adding 50 μl 2 M sulfuric acid to stop the reaction. Cutoff value was calculated as mean OD value of the negative control. If the mean absorbance value of the negative control was lower than 0.105, cutoff value was treated as 0.105. Results were expressed in S/CO value, which was calculated as the ratio of the OD value obtained with the test sample to the cutoff value determined concurrently. The S/CO of 5 or higher was scored as strongly positive reaction; values of 2.1-4.9 as weakly positive and the S/CO of less than 2.1 was scored as negative of humoral immune reaction. Goat anti rabbit IgG-HRP antibody, goat anti human IgG-HRP antibody and goat anti human IgM-HRP antibody were purchased from Bethyl Laboratories, USA.
Epitopes stimulating an IgM response in pooled acute sera
The ELISA results screening pooled acute disease sera were shown in Figure 1. The majority of human IgM epitopes were mapped to VP2 and VP3 proteins with peptides vp2-6, vp2-21, vp2-40, vp2-50, vp3-10, vp3-15 and vp3-24 all judged as strongly positive reaction. While in VP1 protein, only one peptide (vp1-14) showed a strong response, and another peptide (vp1-70) exhibited a weakly positive reaction (Figure 1).
Epitope mapping using individual acute stage serum samples
Individual serum of acute stage disease was screened (Table 1). The panel of synthetic peptides that had the S/CO greater than 5 in Figure 1 were recognized by individual acute stage serum. A total of 10 human anti-EV71 IgM epitopes (vp1-14 of VP1;vp2-6, vp2-21, vp2-40 and, vp2-50 of VP2;vp3-10, vp3-12, vp3-15, vp3-24, vp3-75 of VP3) were revealed.
Mapping human anti EV71 IgG epitopes in convalescent sera
The convalescent serum samples from eight infected individuals were pooled and detected by an indirect ELISA assay to map IgG epitopes. The results showed a single strongly positive (vp1-15) and two weakly positive (vp1-12 and vp1-14) IgG epitopes in VP1 peptide. By contrast, only scattered weakly positive results were detected when screening the synthetic peptides of VP2 and VP3 (Figure 2).
Identification of rabbit anti EV71 IgG epitopes
The panels of synthetic peptides were also screened using a rabbit immunized convalescent sera inactivated by EV71 BJ08 strain. Pre-immunization serum was used as a negative control. The results showed that peptides vp1-14, vp1-31, vp1-54 and vp1-71 in VP1 protein reacted strongly with the sera, while only weakly positive reactions were detected for peptides in VP2 and VP3 (Figure 3).
The structural protein VP1 has usually been considered as an indicator of eliciting a protective immune response after EV71 infection. Consequently, most previous studies aimed at identifying linear humoral epitopes for EV71 were focused on this viral protein. Using 95 overlapping synthetic peptides spanning VP1, Foo, et al. found that two peptides, SP55 (amino acids 162-177: PESRESLAWQTATNPC) and SP70 (amino acids 208-222: YPTFGEHKQEKDLEYC) were able to induce neutralizing antibodies against EV71 using an in vitro microneutralization assay and a neonate mouse challenge assay . A monoclonal antibody (clone 22A12) elicited by SP55 and SP70 immunization was found possessing strong neutralizing activity against EV71 using in vitro neutralization assay . Miao, et al. developed an EV71/Cox A16-bispecific MAb using VP1 of EV71, which successfully improved a high-quality EV identification kit, and could be used as a diagnostic tool for identifying a wide range of EVs isolated from infected patients . VP2 and VP3 were under certain immune pressure since they are also exposed outside of the EV71 viral capsid. It is necessary to explore epitopes on VP2 and VP3. Liu, et al. screened a panel of 153 overlapping synthetic peptides covering the entire sequences of VP1, VP2 and VP3 of EV71. VP2-28 and VP1-43 were recognized by neutralizing antisera (IgG) generated from rabbit and murine, respectively .
Over the past decade, EV71 outbreak has frequently occurred in the Asia-Pacific [2–8]. It is the urgent to understand human IgM and IgG epitopes in order to provide the basis for the development of vaccines and diagnostic reagents. In the current study, the strongest reaction to VP1 peptide vp1-15 was obtained in convalescent sera from infected children. The immunized rabbit sera showing positive epitopes reaction were also primarily located on VP1 protein. The peptide vp1-14 had the strongest reaction, followed by gradually decreased reactive peptides vp1-31, vp1-54 and vp1-71. The positive reaction in various degrees for immunized rabbit sera and convalescent human sera may reflect different levels of virus infection and inactivated virus immunization. Overall, these results were consistent with the previous reports [11, 13, 20–22].
Detecting an IgM response is important for early diagnosis of infectious diseases [16, 19, 23]. However, no IgM epitopes have been identified for EV71 infection to date. Although VP1 contains the major identified epitopes, VP2 and VP3 located on the outside of the viral particle may also be associated with a protective immune response occurred upon or after infection. Consistent with this assumption, the current study identified several clearly reactive epitopes in VP2 and VP3 although their reactions were not so strong. Ten human EV71 IgM epitopes were identified for the first time, and all identified peptides were positively reacted to 8 tested sera, which indicated that EV71 infection may consistently induce multi-epitope anti EV71 IgM response.
Comparison the distribution of immune-reactive IgM and IgG epitopes, our data showed that IgM epitopes were mainly located in VP2 and VP3 capsid proteins, while only one peptide (vp1-14) was located in VP1 eliciting a strong IgM reaction. Another peptide (vp1-15) located in VP1 protein evoked a strong IgG response (Table 2).
In conclusion, our data, for the first time, mapped human anti EV71 IgM and IgG epitopes to the VP1, VP2 and VP3 capsid proteins. These results are valuable for the evaluation of EV71 vaccine immunogenicity and the development of early diagnostic reagents.
Enzyme-linked immunosorbent assay
Hand foot and mouth disease
Specific pathogen Free
Polymerase chain reaction
Centers for disease control
Phosphate buffered saline containing 0.05% Tween-20
Sample optical densities value/Cutoff value
United States of America.
Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, Shih SR, Liu CC, Wu MH: The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis 2002,34(2):52-57. 10.1086/338819
Sanders SA, Herrero LJ, McPHie K, Chow SS, Craig ME, Dwyer DE, Rawlinson W, McMinn PC: Molecular epidemiology of enterovirus 71 over 2 decades in an Australian urban community. Arch Virol 2006,151(5):1003-1013. 10.1007/s00705-005-0684-9
Sato C, Syoji M, Ueki Y, Sato Y, Okimura Y, Saito N, Kikuchi N, Yagi T, Numakura H: Isolation of enterovirus 71 from patients with hand, foot and mouth disease in a local epidemic on March 2006, in Miyagi prefecture, Japan. Jpn J Infect Dis 2006,59(5):348.
Chang LY: Enterovirus 71 in Taiwan. Pediatr Neonatol 2008,49(4):103-112. 10.1016/S1875-9572(08)60023-6
Tee KK, Takebe Y, Kamarulzaman A: Emerging and re-emerging viruses in Malaysia, 1997-2007. Int J Infect Dis 2009,13(3):307-318. 10.1016/j.ijid.2008.09.005
Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, Qi J: Enterovirus 71 outbreak in the People's Republic of China in 2008. Clin Microbiol 2009,47(7):2351-2352. 10.1128/JCM.00563-09
Mao LX, Wu B, Bao WX, Han FA, Xu L, Ge QJ, Yang J, Yuan ZH, Miao CH, Huang XX, Zhang C, Xu H: Epidemiology of hand, foot, and mouth disease and genotype characterization of enterovirus 71 in Jiangsu, China. J Clin Virol 2010,49(2):100-104. 10.1016/j.jcv.2010.07.009
Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, An HQ, Li DX, Wang SW, Xu AQ, Wang ZJ, Xu WB: An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009,44(4):262-267. 10.1016/j.jcv.2009.02.002
Palacios G, Oberste MS: Enteroviruses as agents of emerging infectious diseases. J Neurovirol 2005,11(5):424-433. 10.1080/13550280591002531
Jin Q: Medical Molecular Virology. Beijing: Science Press; 2001:606-613.
Foo DG, Alonso S, Chow VT, Poh CL: Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007,9(11):1299-1306. 10.1016/j.micinf.2007.06.002
Tan CS, Cardosa MJ: High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol 2007,152(6):1069-1073. 10.1007/s00705-007-0941-1
Foo DG, Alonso S, PHoon MC, Chow VT, Ramachandran NP, Poh CL: Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007,125(1):61-68. 10.1016/j.virusres.2006.12.005
Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS: Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001,20(5-6):895-904. 10.1016/S0264-410X(01)00385-1
Yao X, Mao QY, Huang WJ, He P, Zhou C, Zhang W, Liang ZL, Li FX, Wang JZ: Genetic characteristic of enterovirus 71 complete genome isolated in Beijing, 2008. Zhonghua Liu Xing Bing Xue Za Zhi 2009,30(7):729-732.
Xu F, Yan Q, Wang H, Niu J, Li L, Zhu FC, He SZ, Zhang SY, Weng ZX, Cheng T, Cai YJ, He DL, Chen YX, Ge SX, Yeo AET, Zhang J, Ng MH, Xia NS: Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One 2010,5(6):e11388. 10.1371/journal.pone.0011388
Liang ZL, Mao QY, Gao Q, Li XL, Dong CH, Yu X, Yao X, Li FX, Yin WD, Li QH, Shen XL, Wang JZ: Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011,29(52):9668-9674. 10.1016/j.vaccine.2011.10.018
Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, Guo M, Shen X, Sun L, Bi S: Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 2009,390(4):1126-1128. 10.1016/j.bbrc.2009.09.103
Miao LY, Pierce C, Gray-Johnson J, DeLotell J, Shaw C, Chapman N, Yeh E, Schnurr D, Huang YT: Monoclonal antibodies to VP1 recognize a broad range of enteroviruses. J Clin Microbiol 2009,47(10):3108-3113. 10.1128/JCM.00479-09
Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KHW, Sia C, Chong P: Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011, 29: 4362-4372. 10.1016/j.vaccine.2011.04.010
Foo DG, Ang RX, Alonso S, Chow VT, Quak SH, Poh CL: Identification of immunodominant VP1 linear epitope of enterovirus71(EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in western blots. Clin Microbiol Infect 2008,14(3):286-288. 10.1111/j.1469-0691.2007.01904.x
Cello J, Samuelson A, Stålhandske P, Svennerholm B, Jeansson S, Forsgren M: Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides. J Clin Microbiol 1993,31(4):911-916.
Wang SY, Lin TL, Chen HY, Lin TS: Early and rapid detection of enterovirus 71 infection by an IgM-capture ELISA. J Virol Methods 2004,119(1):37-43. 10.1016/j.jviromet.2004.02.017
The authors wish to thank the assistance from Jiangsu Provincial Center for Disease Prevention and Control for sample collection and follow-up visits. This work was supported by National Science Project (No. 2008BAI69B01) and National 11th Five Major Special Projects (No. 2009ZX10004-804) Funding Program.
The authors declare that they have no competing interests.
GF and WYP carried out the laboratory experiments, analyzed the data, interpreted the results and drafted the manuscript. YX and MQY performed molecular genetic studies and sequence alignment. ZFC contributed to specimen collection and clinical diagnosis. LZL and GF participated in the design of the study and performed the statistical analysis. WJZ, LFX, LZL, ZFC, LFM, YJY, LS conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.